Asset profile
Dihydroergotamine mesylate/Dipyrone/Caffeine (Cefaliv)
Unknown / undisclosed
Evidence outlook
Approved: the acute treatment of migraine headaches with or without aura and the acute treatment of... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
52 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 52 same-indication; 51 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv): this drug | Not yet studied | — | — | ||
| Almotriptan (Axert) | Approved | Small molecule | — | ||
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | — | ||
| Atogepant (Qulipta) | Approved | Small molecule | — | ||
| Celecoxib (Elyxyb) | Approved | Small molecule | — | ||
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | ||
| Dihydroergotamine (Atzumi) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Brekiya) | Approved | — | — | ||
| Dihydroergotamine Mesylate (D.H.E. 45) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Migranal) | Approved | — | — | ||
| Divalproex Sodium (Depakote ER) | Approved | — | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Eletriptan (Relpax) | Approved | Small molecule | — | ||
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | — | ||
| Erenumab (Aimovig) | Approved | Monoclonal antibody | — | ||
| Ergotamine / Caffeine (Cafergot) | Approved | — | — |
…and 37 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.